90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y
TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable
intrahepatic cholangiocarcinoma (ICC).
Phase:
N/A
Details
Lead Sponsor:
Medical University of South Carolina Samuel Lewis Cooper, MD